Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Page 1
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Ghofrani HA, et al. Among authors: simonneau g. Lancet Respir Med. 2024 Apr;12(4):e21-e30. doi: 10.1016/S2213-2600(24)00027-4. Lancet Respir Med. 2024. PMID: 38548406 Clinical Trial.
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. ...
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thr …
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.
Delcroix M, de Perrot M, Jaïs X, Jenkins DP, Lang IM, Matsubara H, Meijboom LJ, Quarck R, Simonneau G, Wiedenroth CB, Kim NH. Delcroix M, et al. Among authors: simonneau g. Lancet Respir Med. 2023 Sep;11(9):836-850. doi: 10.1016/S2213-2600(23)00292-8. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591299 Review.
Further work is needed to optimise the use and combination of multimodal therapeutic options in CTEPH to improve long-term outcomes for patients....
Further work is needed to optimise the use and combination of multimodal therapeutic options in CTEPH to improve long-term outcomes f …
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension.
Coghlan JG, Gaine S, Channick R, Chin KM, du Roure C, Gibbs JSR, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson VF, Galiè N. Coghlan JG, et al. Among authors: simonneau g. ERJ Open Res. 2023 Jan 16;9(1):00456-2022. doi: 10.1183/23120541.00456-2022. eCollection 2023 Jan. ERJ Open Res. 2023. PMID: 36687361 Free PMC article.
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes. Post hoc analyses of GRIPHON (NCT01106014) and exploratory analyses of TRITON (NCT02558231) suggested benefit of early selexipag initiat …
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcom …
The evolving landscape of pulmonary arterial hypertension clinical trials.
Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, Zannad F, Gomberg-Maitland M, McLaughlin V, Simonneau G, Humbert M; Evolving Landscape of Pulmonary Arterial Hypertension and Redesigning Pulmonary Arterial Hypertension Clinical Trials Task Force of the 18th Global CardioVascular Clinical Trialists Forum. Weatherald J, et al. Among authors: simonneau g. Lancet. 2022 Nov 26;400(10366):1884-1898. doi: 10.1016/S0140-6736(22)01601-4. Lancet. 2022. PMID: 36436527 Review.
Pulmonary arterial hypertension trial design has shifted from short-term submaximal exercise capacity as a primary endpoint, to larger clinical event-driven trial outcomes. ...
Pulmonary arterial hypertension trial design has shifted from short-term submaximal exercise capacity as a primary endpoint, to large …
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R, Delcroix M, Galié N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O, Torbicki A, Boyanova N, Chamitava L, Stein C, Channick RN. Souza R, et al. Among authors: simonneau g. Adv Ther. 2022 Sep;39(9):4374-4390. doi: 10.1007/s12325-022-02199-x. Epub 2022 Jul 12. Adv Ther. 2022. PMID: 35819570 Free PMC article. Clinical Trial.
Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in PAH patients. ...RESULTS: Of 742 patients randomised in SERAPHIN, 550 (74.1%) entered SERAPHIN OL (OL safety set); 242 patients were randomised to maciten …
Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in PAH patients. …
Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.
Simonneau G, Dorfmüller P, Guignabert C, Mercier O, Humbert M. Simonneau G, et al. Ann Cardiothorac Surg. 2022 Mar;11(2):106-119. doi: 10.21037/acs-2021-pte-10. Ann Cardiothorac Surg. 2022. PMID: 35433354 Free PMC article. Review.
CTEPH is a common cause of pulmonary hypertension (PH) with distinct management strategy including pulmonary endarterectomy, balloon pulmonary angioplasty, long-term anticoagulation and PH drugs targeting endothelial cell dysfunction. ...
CTEPH is a common cause of pulmonary hypertension (PH) with distinct management strategy including pulmonary endarterectomy, balloon pulmona …
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension.
Humbert M, Simonneau G, Pittrow D, Delcroix M, Pepke-Zaba J, Langleben D, Mielniczuk LM, Escribano Subias P, Snijder RJ, Barberà JA, Klotsche J, Meier C, Hoeper MM. Humbert M, et al. Among authors: simonneau g. J Heart Lung Transplant. 2022 Jun;41(6):716-721. doi: 10.1016/j.healun.2022.02.002. Epub 2022 Feb 11. J Heart Lung Transplant. 2022. PMID: 35305871 Free article.
Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were higher in the NOAC group, although the numbers of events were small. Further studies are required to determine the long-term effects …
Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were …
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grünig E, Hoeper MM, Martin N, Mathai SC, McLaughlin VV, Perchenet L, Poch D, Saggar R, Simonneau G, Galiè N. Chin KM, et al. Among authors: simonneau g. J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057. J Am Coll Cardiol. 2021. PMID: 34593120 Free article. Clinical Trial.
Exploratory analyses suggested a possible signal for improved long-term outcomes with initial triple versus initial double oral therapy....
Exploratory analyses suggested a possible signal for improved long-term outcomes with initial triple versus initial double oral thera …
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Benza RL, Ghofrani HA, Grünig E, Hoeper MM, Jansa P, Jing ZC, Kim NH, Langleben D, Simonneau G, Wang C, Busse D, Meier C, Ghio S. Benza RL, et al. Among authors: simonneau g. J Heart Lung Transplant. 2021 Oct;40(10):1172-1180. doi: 10.1016/j.healun.2021.06.020. Epub 2021 Jul 10. J Heart Lung Transplant. 2021. PMID: 34353714 Free article. Clinical Trial.
BACKGROUND: In the Phase III PATENT-1 (NCT00810693) and CHEST-1 (NCT00855465) studies, riociguat demonstrated efficacy vs placebo in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Clinical effects were maintained at …
BACKGROUND: In the Phase III PATENT-1 (NCT00810693) and CHEST-1 (NCT00855465) studies, riociguat demonstrated efficacy vs placebo in patient …
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O. Boucly A, et al. Among authors: simonneau g. Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC. Am J Respir Crit Care Med. 2021. PMID: 34185620 Free article.
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. ...
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. …
132 results